 |
|
|
| |
Improved predictive value for sustained immune control in peginterferon (PEGASYS)-treated HBeAg-positive patients using combined HBsAg and HBV DNA levels at week 24
|
| |
| |
Reported by Jules Levin
Presented at The 47th Annual Meeting of the European Association for the Study of the Liver (EASL), Barcelona, Spain, 18-22 April, 2012
T. Piratvisuth,1 H.L.Y. Chan,2 P. Marcellin,3 C. Wat,4 L. Regep,5 D. Messinger,6 H.-P. Kapprell,7 Z.-M. Lu,8 K.X. Luo9
1NKC Institute of Gastroenterology and Hepatology, Department of Internal Medicine, Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Thailand;2Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; 3Service d'Hepatologie and INSERM CRB3/U773, University Paris-Diderot, Clichy, France; 4Roche Products Limited, Welwyn Garden City, United Kingdom; 5F. Hoffmann-La Roche, Basel, Switzerland; 6IST GmbH, Mannheim, Germany; 7Abbott GmbH and Co. KG, Wiesbaden, Germany; 8Department of Infectious Diseases, Ruijin Hospital, Shanghai, China; 9Department of Infectious Diseases, Nanfang Hospital, Guangzhou, China
|
| |
|
|
|
|
|
